Valore202020212022202320242025TTMSpese di vendita, generali e amministrative22.08 B24.66 B24.77 B21.51 B22.87 B23.68 B24.6 BRicerca e sviluppo12.16 B14.71 B14.6 B483 M1.84 B109 M14.97 BReddito operativo14.67 B18.65 B18.37 B30.43 B31.49 B35.12 B16.9 BProventi non operativi, Totale-3 B-672 M-1.71 B-5.74 B-3.58 B8.01 B547 MOneri finanziari, al netto degli interessi capitalizzati201 M183 M276 M772 M755 M971 M1.04 BProventi non operativi, esclusi gli oneri finanziari-299 M-366 M-114 M123 M363 M-169 M-86 MEntrate/uscite straordinarie-2.9 B-489 M-1.87 B-6.63 B-4.69 B7.21 B-406 MUtile al lordo delle imposte16.5 B22.78 B21.73 B15.06 B16.69 B32.58 B24.94 BQuota di utile———————Imposte1.78 B1.9 B3.78 B1.74 B2.62 B5.78 B3.9 BInteressi di minoranza———————Altri proventi/oneri al netto delle imposte———————Utile netto al lordo delle attività cessate14.71 B20.88 B17.94 B13.33 B14.07 B26.8 B21.04 BAttività cessate———21.83 B00—Utile netto14.71 B20.88 B17.94 B35.15 B14.07 B26.8 B21.04 BRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari14.71 B20.88 B17.94 B35.15 B14.07 B26.8 B21.04 BUtile base per azione (EPS base)5.597.936.8313.885.8411.138.73Utile diluito per azione (EPS diluito)5.517.816.7313.725.7911.038.63Numero medio di azioni ordinarie in circolazione2.63 B2.63 B2.63 B2.53 B2.41 B2.41 B—Azioni diluite in circolazione2.67 B2.67 B2.66 B2.56 B2.43 B2.43 B—EBITDA21.9 B25.95 B25.3 B37.91 B38.83 B42.62 B21.03 BEBIT14.67 B18.65 B18.37 B30.43 B31.49 B35.12 B16.9 BCosto del fatturato28.43 B29.86 B31.09 B26.55 B27.47 B30.26 B31 BAltri costi del venduto———————Ammortamento e svalutazione (liquidità)7.23 B7.39 B6.97 B7.49 B7.34 B7.5 B7.74 B
Johnson & Johnson Common Stock
Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey.
The company operates 2 divisions: Innovative Medicine and MedTech. Major products produced by the Innovative Medicine division are CARVYKTI for multiple myeloma; DARZALEX, also for multiple myeloma; ERLEADA, for prostate cancer; REMICADE, for inflammatory diseases; SIMPONI/SIMPONI ARIA, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis; STELARA, for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; TREMFYA, for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis; INVEGA SUSTENNA/XEPLION, for schizophrenia; SPRAVATO, a nasal spray for depression; OPSUMIT /OPSYNVI for pulmonary arterial hypertension; and UPTRAVI for pulmonary arterial hypertension. The MedTech division produces products used for cardiovascular, orthopaedics, surgery, and vision treatments.
The company is ranked 48th on the Fortune 500 and 42nd on the Forbes Global 2000.